Stock Scorecard
Stock Summary for AnaptysBio Inc (ANAB) - $16.36 as of 12/9/2023 1:37:24 AM EST
Total Score
8 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ANAB
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ANAB
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ANAB
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for ANAB
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for ANAB
Financial Details for ANAB
Company Overview |
|
|---|---|
| Ticker | ANAB |
| Company Name | AnaptysBio Inc |
| Country | USA |
| Description | AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 9/30/2023 |
| Next Earnings Date | 2/28/2024 |
Stock Price History |
|
| Last Day Price | 16.36 |
| Last Day Price Updated | 12/9/2023 1:37:24 AM EST |
| Last Day Volume | 0 |
| Average Daily Volume | N/A |
| 52-Week High | 32.44 |
| 52-Week Low | 13.36 |
| Last Price to 52 Week Low | 22.46 % |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 57.56 |
| Sector PE | 62.37 |
| 5-Year Average PE | -12.10 |
| Free Cash Flow Ratio | 1.05 |
| Industry Free Cash Flow Ratio | 10.37 |
| Sector Free Cash Flow Ratio | 31.15 |
| Current Ratio Most Recent Quarter | 10.92 |
| Total Cash Per Share | 15.54 |
| Book Value Per Share Most Recent Quarter | 4.53 |
| Price to Book Ratio | 3.61 |
| Industry Price to Book Ratio | 4.33 |
| Sector Price to Book Ratio | 19.59 |
| Price to Sales Ratio Twelve Trailing Months | 29.06 |
| Industry Price to Sales Ratio Twelve Trailing Months | 10.29 |
| Sector Price to Sales Ratio Twelve Trailing Months | 5.61 |
Share Statistics |
|
| Total Shares Outstanding | 26,575,200 |
| Market Capitalization | 434,770,272 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Dividend Aristocrat? | False |
| Dividend King? | False |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00 % |
| 5-Year Dividend Payments Count | 0 |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00 % |
| Annual Earnings Growth | -122.72 % |
| Reported EPS 12 Trailing Months | -5.42 |
| Reported EPS Past Year | -4.49 |
| Reported EPS Prior Year | -4.57 |
| Net Income Twelve Trailing Months | -147,821,000 |
| Net Income Past Year | -128,724,000 |
| Net Income Prior Year | -57,796,000 |
| Quarterly Revenue Growth YOY | 156.60 % |
| 5-Year Revenue Growth | 32.40 % |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 413,047,000 |
| Total Cash Past Year | 441,241,000 |
| Total Cash Prior Year | 548,097,000 |
| Net Cash Position Most Recent Quarter | 413,047,000 |
| Net Cash Position Past Year | 441,241,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 1,375,000 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 262,103,000 |
| Total Stockholder Equity Prior Year | 356,428,000 |
| Total Stockholder Equity Most Recent Quarter | 120,383,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.32 |
| MACD Signal | -0.67 |
| 20-Day Bollinger Lower Band | 13.90 |
| 20-Day Bollinger Middle Band | 17.68 |
| 20-Day Bollinger Upper Band | 21.45 |
| Beta | -0.27 |
| RSI | 56.19 |
| 50-Day SMA | 20.63 |
| 200-Day SMA | 23.24 |
System |
|
| Modified | 12/10/2023 5:29:50 AM EST |